Enfuvirtide antiviral activity despite rebound viremia and resistance mutations: Fitness tampering or a case of persistent braking on entering?

Journal of Infectious Diseases

Volumn 195, Issue 3, 2007, Pages 318-321

  Morse, Caryn ^a   Maldarelli, Frank ^b  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; ENFUVIRTIDE; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA;

ANTIVIRAL ACTIVITY; CD4+ T LYMPHOCYTE; DRUG EFFICACY; DRUG WITHDRAWAL; EDITORIAL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IC 50; IMMUNE RESPONSE; INJECTION SITE REACTION; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; REBOUND; TREATMENT OUTCOME; VIREMIA; VIRUS INHIBITION; VIRUS ISOLATION; VIRUS MUTATION; VIRUS RESISTANCE;

EID: 33846455806     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/510539     Document Type: Editorial

References (41)

1. Bonhoeffer S, Nowak MA. Pre-existence and emergence of drug resistance in HIV-1 infection. Proc Biol Sci 1997; 264:631-7.
2. Coffin JM. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science 1995; 267:483-9.
3. Deeks SG, Hecht FM, Swanson M, et al. HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: response to both initial and salvage therapy. AIDS 1999; 13:F35-43.
4. Fatkenheuer G, Theisen A, Rockstroh J, et al. Virological treatment failure of protease inhibitor therapy in an unselected cohort of HIV-infected patients. AIDS 1997; 11:F113-6.
5. Hammer SM, Vaida F, Bennett KK, et al. Dual vs single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial. JAMA 2002; 288:169-80.
6. Manfredi R, Chiodo F. Limits of deep salvage antiretroviral therapy with nelfinavir plus either efavirenz or nevirapine, in highly pretreated patients with HIV disease. Int J Antimicrob Agents 2001; 17:511-6.
7. Gulick RM, Ribaudo HJ, Shikuma CM, et al. Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trial. JAMA 2006; 296: 769-81.
8. Gulick RM, Ribaudo HJ, Shikuma CM, et al. Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. N Engl J Med 2004; 350: 1850-61.
9. Walmsley S, Bernstein B, King M, et al. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N Engl J Med 2002; 346:2039-46.
10. US Department of Health and Human Services Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents-October 10, 2006. Available at: http://aidsinfo.nih.gov/Guidelines/GuidelineDetail.aspx?MenuItem=Guidelines &Search=Off&GuidelineID=7&ClassID=1. Accessed 20 December 2006.
11. Campbell TB, Shulman NS, Johnson SC, et al. Antiviral activity of lamivudine in salvage therapy for multidrug-resistant HIV-1 infection. Clin Infect Dis 2005; 41:236-42.
12. Deeks SG, Hoh R, Neilands TB, et al. Interruption of treatment with individual therapeutic drug classes in adults with multidrug-resistant HIV-1 infection. J Infect Dis 2005; 192:1537-14.
13. Maggiolo F, Callegaro A, Ripamonti D, et al. In vivo determination of stavudine activity in the presence of TAM [abstract 706]. In: Programs and abstracts of the 12th Conference on Retroviruses and Opportunistic Infections (Boston). Alexandria, VA: Foundation for Retrovirology and Human Health, 2005:323.
14. Maldarelli FP, Palmer S, Kearney S, et al. Short duration, single drug discontinuation to assess the activity of individual drugs in patients failing antiretroviral therapy. Antivir Ther 2003; 8:S149.
15. Deeks SG, Hoh R, Neilands TB, et al. Interruption of enfuvirtide in HIV-1-infected adults with incomplete viral suppression on an enfuvirtide-based regimen. J Infect Dis 2007; 195:387-91 (in this issue).
16. Chen RY, Kilby JM, Saag MS. Enfuvirtide. Expert Opin Investig Drugs 2002; 11:1837-43.
17. Lalezari JP, Henry K, O'Hearn M, et al. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med 2003; 348:2175-85.
18. Lazzarin A, Clotet B, Cooper D, et al. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N Engl J Med 2003; 348:2186-95.
19. Nelson M, Arasteh K, Clotet B, et al. Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trials. J Acquir Immune Defic Syndr 2005; 40:404-12.
20. Raffi F, Katlama C, Saag M, et al. Week-12 response to therapy as a predictor of week 24, 48, and 96 outcome in patients receiving the HIV fusion inhibitor enfuvirtide in the T-20 versus Optimized Regimen Only (TORO) trials. Clin Infect Dis 2006; 42:870-7.
21. Van Laethem K, Schrooten Y, et al. A genotypic resistance assay for the detection of drug resistance in the human immunodeficiency virus type 1 envelope gene. J Virol Methods 2005; 123:25-34.
22. Chinnadurai R, Munch J, Dittmar MT, Kirchhoff F. Inhibition of HIV-1 group M and O isolates by fusion inhibitors. AIDS 2005; 19: 1919-22.
23. Poveda E, Barreiro P, Rodes B, Soriano V. Enfuvirtide is active against HIV type 1 group O. AIDS Res Hum Retroviruses 2005; 21: 583-5.
24. Labrosse B, Labernardiere JL, Dam E, et al. Baseline susceptibility of primary human immunodeficiency virus type 1 to entry inhibitors. J Virol 2003; 77:1610-3.
25. Melby T, Sista P, DeMasi R, Kirkland T, et al. Characterization of envelope glycoprotein gp41 genotype and phenotypic susceptibility to enfuvirtide at baseline and on treatment in the phase III clinical trials TORO-1 and TORO-2. AIDS Res Hum Retroviruses 2006; 22:375-85.
26. Perez-Alvarez L, Carmona R, Ocampo A, et al. Long-term monitoring of genotypic and phenotypic resistance to T20 in treated patients infected with HIV-1. J Med Virol 2006; 78:141-7.
27. Sista PR, Melby T, Davison D, et al. Characterization of determinants of genotypic and phenotypic resistance to enfuvirtide in baseline and on-treatment HIV-1 isolates. AIDS 2004;18:1787-94.
28. Su C, Melby T, DeMasi R, Ravindran P, Heilek-Snyder G. Genotypic changes in human immunodeficiency virus type 1 envelope glycoproteins on treatment with the fusion inhibitor enfuvirtide and their influence on changes in drug susceptibility in vitro. J Clin Virol 2006; 36:249-57.
29. Wei X, Decker JM, Liu H, et al. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob Agents Chemother 2002; 46:1896-905.
30. Xu L, Pozniak A, Wildfire A, et al. Emergence and evolution of enfuvirtide resistance following long-term therapy involves heptad repeat 2 mutations within gp41. Antimicrob Agents Chemother 2005; 49:1113-9.
31. Aquaro S, D'Arrigo R, Svicher V, et al. Specific mutations in HIV-1 gp41 are associated with immunological success in HIV-1-infected patients receiving enfuvirtide treatment. J Antimicrob Chemother 2006; 58:714-22.
32. Kilby JM, Hopkins S, Venetta TM, et al. Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nat Med 1998; 4:1302-7.
33. Melby T, Despirito M, Demasi R, Heilek-Snyder G, Greenberg ML, Graham N. HIV-1 coreceptor use in triple-class treatment-experienced patients: baseline prevalence, correlates, and relationship to enfuvirtide response. J Infect Dis 2006; 194:238-46.
34. Poveda E, Rodes B, Lebel-Binay S, Faudon JL, Jimenez V, Soriano V. Dynamics of enfuvirtide resistance in HIV-infected patients during and after long-term enfuvirtide salvage therapy. J Clin Virol 2005; 34:295-301.
35. Maggiolo F, Callegaro A, Gregis G, et al. In vivo determination of tenofovir antiviral effect in the presence of TAM [abstract 707]. In: Programs and abstracts of the 12th Conference on Retroviruses and Opportunistic Infections (Boston). Alexandria, VA: Foundation for Retrovirology and Human Health, 2005: 323.
36. Reeves JD, Lee FH, Miamidian JL, Jabara CB, Juntilla MM, Doms RW. Enfuvirtide resistance mutations: impact on human immunodeficiency virus envelope function, entry inhibitor sensitivity, and virus neutralization. J Virol 2005; 79:4991-9.
37. Lu J, Sista P, Giguel F, Greenberg M, Kuritzkes DR. Relative replicative fitness of human immunodeficiency virus type 1 mutants resistant to enfuvirtide (T-20). J Virol 2004; 78:4628-37.
38. Labrosse B, Morand-Joubert L, Goubard A, et al. Role of the envelope genetic context in the development of enfuvirtide resistance in human immunodeficiency virus type 1-infected patients. J Virol 2006; 80:8807-19.
39. Lalezari JP, DeJesus E, Northfelt DW, et al. A controlled phase II trial assessing three doses of enfuvirtide (T-20) in combination with abacavir, amprenavir, ritonavir and efavirenz in non-nucleoside reverse transcriptase inhibitor-naive HIV-infected adults. Antivir Ther 2003; 8:279-87.
40. Lalezari JP, Patel IH, Zhang X, et al. Influence of subcutaneous injection site on the steady-state pharmacokinetics of enfuvirtide (T-20) in HIV-1-infected patients. J Clin Virol 2003; 28:217-22.
41. Wheeler DA, Lalezari JP, Kilby JM, et al. Safety, tolerability, and plasma pharmacokinetics of high-strength formulations of enfuvirtide (T-20) in treatment-experienced HIV-1-infected patients. J Clin Virol 2004; 30:183-90.